Clinical Study Results
Research Sponsor: Pearl Therapeutics, Inc., a member of the AstraZeneca Group
Treatment Studied: Albuterol sulfate pressurized inhalation suspension, also
called AS MDI
Study Title: This study was done to learn how different doses of albuterol
sulfate given in an inhaler worked, compared with in a different
inhaler and how safe it was in people with asthma
Thank you!
Thank you for taking part in the clinical study of the treatment AS MDI, also called
albuterol sulfate pressurized inhalation suspension. You and all the participants helped
researchers learn more about AS MDI to help people with asthma.
Pearl Therapeutics, Inc. sponsored this study and thinks it is important to share the
results of the study with you and the public. An independent, non-profit organization
called CISCRP helped prepare this summary of the study results for you. We hope it
helps you understand and feel proud of your important role in medical research.
If you participated in the study and have questions about the results, please speak with
the doctor or staff at your study site.
What is happening with the study now?
You and the other participants were in the study for up to about 6 weeks. The study
started in December 2017 and ended in March 2018. The study took place in the USA. It
included 46 participants.
The sponsor reviewed the data collected when the study ended and created a report of
the results. This is a summary of that report.
1